ST Wanbang announced that its wholly-owned subsidiary Wanbang Pharmaceutical Group Co., Ltd. independently developed the new drug WP107 for the treatment of systemic myasthenia gravis, and recently obtained approval from the US Food and Drug Administration for multi-dose slope climbing clinical trial studies for health trial participants.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.